COVID-19 vaccines have been approved for use early in 2021, with the BioNTech mRNA vaccine (Comirnaty®) being one of the first vaccines made widely available in the market. The BNT162b2 vaccine, which carries a nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein, produces a high serum neutralising antibody titre and antigen-specific T-cell response when administered in two 30µg doses in healthy adults.
Tag Archive for: SARS-CoV-2
Disruption of standard patient care due to the COVID-19 pandemic has been long postulated, and is now supported by a study reported in the Journal of the American College of Cardiology reporting delays in the delivery of essential diagnostic services, particularly for cardiovascular conditions, affecting health outcomes.
While vaccines are starting to become available for the prevention of SARS-Cov-2 infection, it is anticipated that the Coronavirus 2019 (COVID-19) pandemic will continue for at least the next year.